The Latest Breaking News from Roche

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Merck is navigating a looming patent expiration for its blockbuster Keytruda. Now, Merck stock is trading at its highest point in decades.

'Healthcare is a sector that generally holds steady no matter what is happening in the economy,' the research firm said.

While a recession in 2023 looks inevitable amid lingering macro headwinds, experts believe it to be mild. Moreover, amid high hopes for a Santa Claus rally, quality stocks Stellantis (STLA), Albertsons Companies (ACI), Poseida Therapeutics (PSTX), and Civeo (CVEO) could be ideal buys under $30 now. Keep reading….

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.

Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.

Swiss pharmaceutical firm carried out two identical phase 3 trials of gantenerumab, with about 1,000 volunteers in each

"While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer’s dataset to the field," Roche said.

The drug had held promise in earlier trials